Hope for patients with pain
Conquest - Summer 2012
Commonly used drug eliminates morphine tolerance
Seeing children endure chronic pain associated with cancer treatment inspired Howard Gutstein, M.D., professor in MD Anderson’s Department of Anesthesiology and Perioperative Medicine and Department of Biochemistry and Molecular Biology, to focus his research on pain management.
Specifically, he wanted to find the cause of morphine tolerance, which develops over time and makes the drug ineffective for pain relief.
“If I could understand what causes morphine tolerance, I’d finally be able to treat these patients’ pain effectively and alleviate their suffering,” Gutstein says. He discovered the key to understanding morphine tolerance might be a cancer drug already in clinical use.
Gutstein and his colleagues found that the cellular process that causes morphine tolerance can be blocked by a reformulated form of imatinib, a drug commonly used to treat certain kinds of leukemia and gastrointestinal tumors.
Since imatinib, known by the brand name Gleevec®, is already approved for use in humans, Gutstein hopes soon to translate his findings on the reformulation of the drug through animal studies and Phase I trials in humans.
“We may be able to quickly translate this discovery and dramatically reduce the suffering endured by the sickest patients, and not just those with cancer,” Gutstein says.
Blocking tolerance would make lower doses of morphine more effective, also reducing undesirable side effects associated with it, including itchiness, nausea and difficulty breathing.
Reported in the February 2012 edition of Nature Medicine.
Resources: Pain management
Conquest: Summer 2012
- Green medicine
- Going the distance
- When life is good
- Practice makes perfect
- A 'whole' in one center
- When the pipeline dries up
- Frontline: Latest research advances
- Cancer Briefings: Latest MD Anderson news
- Picture This: Beauty/Barber Shop
- Signs of Hope: COLLAGE
- Moving Forward: Jameisha Brown
Audio and PDFs
Care to Comment?
Email the editor to comment on a story or offer suggestions on topics you'd like to see covered in future issues of Conquest and Annual Report.